All articles by Swagath Bandhakavi
Swagath Bandhakavi
Dupixent gains FDA approval for expanded use in adolescents with CRSwNP
The approval of Dupixent for this indication is supported by data from the Phase 3 SINUS-24 and SINUS-52 clinical trials
Pfizer’s Braftovi and Mektovi show long-term benefit in NSCLC Phase 2 trial
The longer-term follow-up results from the PHAROS clinical trial showed encouraging outcomes for both treatment-naïve and previously treated patients
Japan approves CSL and Arcturus Therapeutics’ updated self-amplifying mRNA COVID-19 vaccine for protection against JN.1 strain
Approval underscores CSL and Arcturus Therapeutics’ commitment to delivering disruptive technologies to combat COVID-19 and other respiratory viral diseases to protect public health
Ractigen Therapeutics announces FDA ODD granted to RAG-18 for treatment of DMD and BMD
RAG-18 is a first of its kind saRNA candidate designed to specifically target and activate UTRN gene expression in muscle cells via RNAa mechanism
PhotonPharma secures $2.5m in seed funding to advance clinical trial for ovarian cancer treatment
This vital funding will support the Phase I clinical trial of Innocell, an innovative therapy for the treatment of advanced ovarian cancer
Pfizer’s Abrysvo shows benefit in immunocompromised adults in Phase 3 RSV trial
The MONeT study is evaluating the impact of two doses of the bivalent RSVpreF vaccine in adults aged 18 and older at high risk of severe RSV-associated lower respiratory tract disease
Junshi Biosciences announces acceptance of sNDA for toripalimab as first-line treatment of unresectable/metastatic melanoma
The sNDA is mainly based on the MELATORCH study, a multi-center, randomized, open-label, positive-controlled Phase III clinical study
Absci partners with MSK to develop novel cancer treatments using gen AI
The collaboration will focus on jointly developing up to six cancer therapeutic programmes, making use of Absci’s Integrated Drug Creation platform
Precision BioSciences announces IND clearance by partner TG Therapeutics for investigation of Azer-Cel for multiple sclerosis
Out licensed allogeneic CAR T azer-cel receives IND clearance from U.S. FDA
Avicenna and Molecure partner to advance small molecule drug discovery targeting USP7
The partnership will utilise Molecure’s drug discovery and USP7 biology expertise in conjunction with Avicenna Biosciences’ ML-driven medicinal chemistry platform to identify and develop new drug candidates with improved pharmaceutical properties